Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
PHASE III STUDY COMPARING BEVACIZUMAB PLUS ERLOTINIB TO ERLOTINIB IN PATIENTS WITH UNTREATED NSCLC HARBORING ACTIVATING EGFR MUTATIONS: NEJ026
12 března, 2021 7:09 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer–Non-Small Cell Metastatic Abstract number: 9006 Citation: J Clin Oncol...
NEOADJUVANT CHEMO/IMMUNOTHERAPY FOR THE TREATMENT OF STAGES IIIA RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II MULTICENTER EXPLORATORY STUDY–NADIM STUDY-SLCG
12 března, 2021 7:03 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer–Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract number: 8521 Citation:...
PHASE 2 STUDY OF PEMBROLIZUMAB IN ADVANCED SMALL-CELL LUNG CANCER (SCLC): KEYNOTE-158
12 března, 2021 6:57 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer–Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract number: 8506 Citation:...
PHASE 3 STUDY OF CARBOPLATIN-PACLITAXEL/NAB-PACLITAXEL (CHEMO) WITH OR WITHOUT PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH METASTATIC SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
12 března, 2021 6:51 pmMeeting: 2018 ASCO Annual Meeting Track: Lung Cancer–Non-Small Cell Metastatic Abstract number: 105 Citation: J Clin Oncol...
FRONTLINE PEMBROLIZUMAB AND CHEMOTHERAPY A NEW STANDARD OF CARE IN METASTATIC SQUAMOUS NSCLC
12 března, 2021 6:45 pmJune 3, 2018 Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in...
NOVINKY Z LETOŠNÍHO SETKÁNÍ AMERICAN SOCIETY OF CLINICAL ONCOLOGY
12 března, 2021 6:42 pmNové výsledky protinádorové imunoterapie u nemocných s rakovinou plic dominovaly i letos řadě sekcí včetně plenárního zasedání, na kterém byla...
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
12 března, 2021 6:39 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5529 Authors: He Huang, Li Yang, Yue...
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
12 března, 2021 6:37 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5503 Authors: David S. Miller, Giovanni Scambia,...
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
12 března, 2021 6:34 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5509 Authors: Lukas Rob, Peter Mallmann, Pawel...
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
12 března, 2021 6:31 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5501 Authors: Robert L. Coleman, Danielle Enserro,...